<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03197597</url>
  </required_header>
  <id_info>
    <org_study_id>EUpert IV</org_study_id>
    <nct_id>NCT03197597</nct_id>
  </id_info>
  <brief_title>EUpertstrain 4 Study of Bordetella Pertussis Isolates</brief_title>
  <official_title>EUpertstrain 4 Study of Bordetella Pertussis Isolates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focus on the genetic changes of B. pertussis clinical isolates. For this panels of
      B. pertussis isolates has been collected during four periods in different European countries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B. pertussis is considered as a monomorphic pathogen. However, genetic changes have been
      observed in several antigens (pertussis toxin, pertactin, filamentous haemagglutinin and
      fimbriae) included in the current acellular pertussis vaccines between vaccine strains and
      circulating isolates.

      To study genetic changes in the B. pertussis populations in Europe, four distinct panels have
      been collected: EUpert I in 1999-2001 including 102 isolates, EUpert II in 2004-2005
      including 154 isolates, EUpert III in 2007-2009 including 140 isolates and EUpert IV in
      2012-2015 including 265 isolates. Selection criteria have remained unchanged for all four
      collections, which enables the opportunity to study changes in B. pertussis populations
      during the last 15 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2015</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine antigen deficient (VAD) B. pertussis clinical isolates</measure>
    <time_frame>24 months</time_frame>
    <description>We screened a panel of 265 B. pertussis clinical isolates collected from 9 European countries. We used previously developed ELISA to measure the antigen expression of pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (PRN) and fimbriae 2&amp;3 (Fim2&amp;3). In addition, we used sequencing to further characterize the pertactin gene of the bacteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Study of genetic changes in the B. pertussis genomic content measured by specific molecular methods</measure>
    <time_frame>24 months</time_frame>
    <description>We studied genetic changes in the main virulence genes of B. pertussis. We genotyped pertussis toxin promoter (ptxP), pertactin (PRN), fimbriae3 (Fim3) and pertussis toxin subunit A (ptxA). Serotyping of Fimbriae (Fim), Pulsed-Field Gel Electrophoresis (PFGE) and Multiple-Locus Variable number tandem repeat Analysis (MLVA) were used for further genomic analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association between vaccine antigen deficient (VAD) B. pertussis clinical isolates and their association to the introduction of acellular pertussis vaccination (ACV)</measure>
    <time_frame>24 months</time_frame>
    <description>We studied the association between the frequency of VAD B. pertussis clinical isolates and their association to the introduction of ACV. Data of vaccination schedules by country and number of VAD isolates were collected and compared.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">265</enrollment>
  <condition>Bordetella Pertussis, Whooping Cough</condition>
  <arm_group>
    <arm_group_label>Strain isolation from the nasopharynx</arm_group_label>
    <description>A group of culture positive whooping cough patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Strain isolation from the nasopharynx</intervention_name>
    <description>B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit</description>
    <arm_group_label>Strain isolation from the nasopharynx</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Collection of nasopharyngeal swabs from the human nasopharynx. From the swab, B. pertussis
      bacteria is isolated and cultured and DNA is studied. However, no human DNA is used in the
      measurements.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consists of pertussis culture positive patients from nine European
        countries. From this population, B. pertussis clinical isolates are collected and studied.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  B. pertussis clinical isolates should be collected from subjects from different
             regions and be epidemiologically unrelated.

          -  An equal number of isolates from vaccinated and unvaccinated subjects should be
             collected. Optimally, the isolates are preferred to be selected from individuals less
             than 5 years of age.

          -  For countries with large numbers of isolates in their collections, isolates should be
             randomly selected according to criteria above.

        Exclusion Criteria:

          -  There is no strict exclusion criteria for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiushui He, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Turku</name>
      <address>
        <city>Turku</city>
        <zip>20014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Advani A, Hallander HO, Dalby T, Krogfelt KA, Guiso N, Njamkepo E, von Könnig CH, Riffelmann M, Mooi FR, Sandven P, Lutynska A, Fry NK, Mertsola J, He Q. Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol. 2013 Feb;51(2):422-8. doi: 10.1128/JCM.02036-12. Epub 2012 Nov 21.</citation>
    <PMID>23175253</PMID>
  </reference>
  <reference>
    <citation>Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine. 2009 Oct 9;27(43):6034-41. doi: 10.1016/j.vaccine.2009.07.074. Epub 2009 Aug 8.</citation>
    <PMID>19666155</PMID>
  </reference>
  <reference>
    <citation>Barkoff AM, Mertsola J, Guillot S, Guiso N, Berbers G, He Q. Appearance of Bordetella pertussis strains not expressing the vaccine antigen pertactin in Finland. Clin Vaccine Immunol. 2012 Oct;19(10):1703-4. Epub 2012 Aug 22.</citation>
    <PMID>22914363</PMID>
  </reference>
  <reference>
    <citation>Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N, Mertsola J. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009 Aug;15(8):1206-13. doi: 10.3201/eid1508.081511.</citation>
    <PMID>19751581</PMID>
  </reference>
  <reference>
    <citation>Barkoff AM, Guiso N, Guillot S, Xing D, Markey K, Berbers G, Mertsola J, He Q. A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines. J Immunol Methods. 2014 Jun;408:142-8. doi: 10.1016/j.jim.2014.06.001. Epub 2014 Jun 10.</citation>
    <PMID>24925807</PMID>
  </reference>
  <reference>
    <citation>Caro V, Njamkepo E, Van Amersfoorth SC, Mooi FR, Advani A, Hallander HO, He Q, Mertsola J, Riffelmann M, Vahrenholz C, Von König CH, Guiso N. Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect. 2005 Jun;7(7-8):976-82.</citation>
    <PMID>15994109</PMID>
  </reference>
  <reference>
    <citation>Heikkinen E, Xing DK, Olander RM, Hytönen J, Viljanen MK, Mertsola J, He Q. Bordetella pertussis isolates in Finland: serotype and fimbrial expression. BMC Microbiol. 2008 Sep 25;8:162. doi: 10.1186/1471-2180-8-162.</citation>
    <PMID>18816412</PMID>
  </reference>
  <reference>
    <citation>van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, von König CH, Riffelmann M, Vahrenholz C, Guiso N, Caro V, Njamkepo E, He Q, Mertsola J, Mooi FR. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol. 2005 Jun;43(6):2837-43.</citation>
    <PMID>15956406</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2017</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Turku</investigator_affiliation>
    <investigator_full_name>Qiushui He</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>B. pertussis</keyword>
  <keyword>Acellular vaccination</keyword>
  <keyword>Strain variation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>June 23, 2017</submitted>
    <returned>November 9, 2017</returned>
    <submitted>May 4, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

